Please assess the completion status of the following clinical trial:

Trial Title: A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged from 6 months to 65 years old~* Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum (or mixed with non-falciparum species)~* Asexual P. falciparum parasitaemia: 5,000 to 200,000/uL, de-termined on a thin or thick blood film (In Cambodia patients with a parasitaemia of 16 to 200,000/uL are eligible. In DRC patients with a parasitaemia of 10,000 to 250,000/ul are eligi-ble)~* Fever defined as \>/= 37.5°C tympanic temperature or a history of fever within the last 24 hours~* Written informed consent (by parent/guardian in case of children)~* Willingness and ability of the patients or parents/guardians to comply with the study protocol for the duration of the study~Exclusion Criteria:~* Signs of severe/complicated malaria~* Haematocrit \< 25% or Hb \< 5 g/dL at screening (DRC: Hct\<15% and Hb \<5 g/dL due to high prevalence of anemia).~* Acute illness other than malaria requiring treatment~* For females: pregnancy, breast feeding~* Patients who have received artemisinin or a derivative or an artemisinin containing combination therapy (ACT) within the previous 7 days~* Treatment with mefloquine in the 2 months prior to presentation will be an exclusion criteria in the DHA-P+MQ sites~* History of allergy or known contraindication to artemisinins, or to the ACT or TACT to be used at the site e.g. neuropsychiatric disorders will be a contraindication for the use of mefloquine.~* Previous splenectomy~* QTc-interval \> 450 milliseconds at moment of presentation~* Documented or claimed history of cardiac conduction problems~* Earlier participation within the TRACII trial or another trial in the previous 3 months.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ACT-arms (Type: ACTIVE_COMPARATOR): 1.1 Artemether-lumefantrine for 3 days.~1.2 Dihydroartemisinin-piperaquine for 3 days~1.3 Artesunate-Mefloquine for 3 days
- TACT-arms (Type: ACTIVE_COMPARATOR): 2.1: Artemether-lumefantrine for 3 days.plus: Amodiaquine for 3 days.~2.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.~2.3 Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).